Relay Therapeutics will present data at a medical meeting Friday that give investors and oncologists the first look at RLY-4008, its drug to treat a form of liver cancer.
“So far in the clinic, 4008 has done everything we designed it to do from the outset,” Don Bergstrom, Relay’s chief medical officer, told STAT.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
